Utility of Head-to-Head Studies in Psoriasis Management

Video content above is prompted by the following:

There are several head-to-head studies of IL-17 inhibitors against other drug classes used in psoriasis as well as other IL-17 inhibitors. What head-to-head data have you found most compelling?

• BE RADIANT—bimekizumab vs secukinumab
• BE VIVID—bimekizumab vs ustekinumab
• CLARITY—secukinumab vs ustekinumab
• COBRA—brodalumab vs guselkumab
• IXORA-R—ixekizumab vs guselkumab
• IMMerge—risankizumab vs Secukinumab
• BE BOLD study of risankizumab vs bimekizumab in PsA announced (press release)

What is the clinical utility of head-to-head studies, and how do you use this data to navigate the psoriasis treatment landscape?